Reported Earnings • May 07
Full year 2026 earnings: EPS misses analyst expectations Full year 2026 results: EPS: ₹48.77 (up from ₹36.43 in FY 2025). Revenue: ₹92.2b (up 17% from FY 2025). Net income: ₹9.24b (up 36% from FY 2025). Profit margin: 10.0% (up from 8.6% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.0%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Announcement • Apr 29
Emcure Pharmaceuticals Limited to Report Q4, 2026 Results on May 05, 2026 Emcure Pharmaceuticals Limited announced that they will report Q4, 2026 results on May 05, 2026 Reported Earnings • Feb 05
Third quarter 2026 earnings: EPS and revenues exceed analyst expectations Third quarter 2026 results: EPS: ₹12.16 (up from ₹8.12 in 3Q 2025). Revenue: ₹23.7b (up 21% from 3Q 2025). Net income: ₹2.31b (up 50% from 3Q 2025). Profit margin: 9.7% (up from 7.8% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Announcement • Jan 22
Emcure Pharmaceuticals Limited to Report Q3, 2026 Results on Feb 04, 2026 Emcure Pharmaceuticals Limited announced that they will report Q3, 2026 results on Feb 04, 2026 Announcement • Nov 22
Emcure Pharmaceuticals Limited Announces Resignation of Chetan Sharma as Company Secretary and Compliance Officer, Effective November 24, 2025 Emcure Pharmaceuticals Limited announced that Mr. Chetan Sharma (FCS: 8352) has submitted his resignation from the post of Company Secretary and Compliance Officer & Key Managerial Personnel of the Company, with effect from close of business hours on November 24, 2025, to pursue opportunities outside the organization. Reported Earnings • Nov 12
Second quarter 2026 earnings released: EPS: ₹12.85 (vs ₹10.33 in 2Q 2025) Second quarter 2026 results: EPS: ₹12.85 (up from ₹10.33 in 2Q 2025). Revenue: ₹22.7b (up 14% from 2Q 2025). Net income: ₹2.43b (up 25% from 2Q 2025). Profit margin: 11% (up from 9.7% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Announcement • Nov 03
Emcure Pharmaceuticals Limited to Report Q2, 2026 Results on Nov 11, 2025 Emcure Pharmaceuticals Limited announced that they will report Q2, 2026 results on Nov 11, 2025 Announcement • Aug 29
Emcure Pharmaceuticals Limited Approves Final Dividend for the Financial Year Ended on March 31, 2025 Emcure Pharmaceuticals Limited at its AGM held on August 28, 2025, approved to declare Final dividend of INR 3 per Equity Share on Face Value of INR 10/-each (Rupees Ten only) for the Financial Year ended on March 31, 2025. Price Target Changed • Aug 09
Price target increased by 13% to ₹1,653 Up from ₹1,458, the current price target is an average from 4 analysts. New target price is 19% above last closing price of ₹1,385. Stock is up 7.7% over the past year. The company is forecast to post earnings per share of ₹50.40 for next year compared to ₹36.43 last year. Announcement • Aug 04
Emcure Pharmaceuticals Limited, Annual General Meeting, Aug 28, 2025 Emcure Pharmaceuticals Limited, Annual General Meeting, Aug 28, 2025, at 11:00 Indian Standard Time. Reported Earnings • Aug 03
Full year 2025 earnings released: EPS: ₹36.43 (vs ₹27.54 in FY 2024) Full year 2025 results: EPS: ₹36.43 (up from ₹27.54 in FY 2024). Revenue: ₹79.6b (up 20% from FY 2024). Net income: ₹6.81b (up 37% from FY 2024). Profit margin: 8.6% (up from 7.5% in FY 2024). The increase in margin was driven by higher revenue. Announcement • Jul 28
Emcure Pharmaceuticals Limited to Report Q1, 2026 Results on Aug 07, 2025 Emcure Pharmaceuticals Limited announced that they will report Q1, 2026 results on Aug 07, 2025 Announcement • Jun 22
Emcure Pharmaceuticals Limited (NSEI : EMCURE) agreed to acquire the remaining 20.42% stake in Zuventus Healthcare Ltd. for INR 7.2 billion. Emcure Pharmaceuticals Limited (NSEI : EMCURE) agreed to acquire the remaining 20.42% stake in Zuventus Healthcare Ltd. for INR 7.2 billion on June 21, 2025. Upon completion of the transaction, Emcure Pharmaceuticals Limited will own 100% stake in Zuventus Healthcare Ltd.
For the period ending March 31, 2025, Zuventus Healthcare Ltd. reported total revenue of INR 10.8 billion and net income of INR 1.3 billion.
The transaction is subject to the approval of the board of Emcure Pharmaceuticals Limited. The deal has been approved by the board of Emcure Pharmaceuticals Limited. The expected completion of the transaction is by September 30, 2025. Valuation Update With 7 Day Price Move • May 29
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1,351, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 32x in the Pharmaceuticals industry in India. Simply Wall St's valuation model estimates the intrinsic value at ₹681 per share. Reported Earnings • May 23
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: ₹36.43 (up from ₹27.54 in FY 2024). Revenue: ₹79.6b (up 20% from FY 2024). Net income: ₹6.81b (up 37% from FY 2024). Profit margin: 8.6% (up from 7.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.2%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Announcement • May 13
Emcure Pharmaceuticals Limited to Report Q4, 2025 Results on May 22, 2025 Emcure Pharmaceuticals Limited announced that they will report Q4, 2025 results at 12:08 PM, Indian Standard Time on May 22, 2025 Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹1,095, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Simply Wall St's valuation model estimates the intrinsic value at ₹669 per share. Valuation Update With 7 Day Price Move • Feb 13
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹1,063, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 29x in the Pharmaceuticals industry in India. Simply Wall St's valuation model estimates the intrinsic value at ₹670 per share. Reported Earnings • Feb 07
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: EPS: ₹8.12 (up from ₹5.84 in 3Q 2024). Revenue: ₹19.7b (up 14% from 3Q 2024). Net income: ₹1.54b (up 45% from 3Q 2024). Profit margin: 7.8% (up from 6.1% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Announcement • Jan 24
Emcure Pharmaceuticals Limited to Report Q3, 2025 Results on Feb 06, 2025 Emcure Pharmaceuticals Limited announced that they will report Q3, 2025 results on Feb 06, 2025 Announcement • Nov 29
Emcure Pharmaceuticals Limited Announces the Resignation of Aravamuthan Balaji, President - It & Digital and Senior Management Personnel, with Effect from Close of Business Hours on December 31, 2024 Emcure Pharmaceuticals Limited announced the resignation of Mr. Aravamuthan Balaji, President - IT & Digital and Senior Management Personnel, has submitted his resignation with effect from close of business hours on December 31, 2024 on account of personal reasons. Reported Earnings • Nov 08
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: ₹10.33 (up from ₹7.70 in 2Q 2024). Revenue: ₹20.4b (up 22% from 2Q 2024). Net income: ₹1.95b (up 40% from 2Q 2024). Profit margin: 9.5% (up from 8.4% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Announcement • Nov 05
Avet Pharmaceuticals Inc Announces Settlement with the State Attorney General Plaintiffs in Generic Pharmaceuticals Pricing Antitrust Litigation Avet Pharmaceuticals Inc., formerly known as Heritage Pharmaceuticals Inc. announced that it has entered into a settlement agreement with the State Attorneys General Plaintiffs (the "State AG Plaintiffs") in the Generic Pharmaceuticals Pricing Antitrust Litigation formerly pending in the U.S. District Court, Eastern District of Pennsylvania, and now pending in the U.S. District Court for the District of Connecticut. The State AG Plaintiffs include fifty U.S. states and territories that have asserted claims against Avet and other pharmaceutical companies, on their own behalf and on behalf of their respective constituencies, based upon the purchase of drugs that were the subject of the lawsuit during the relevant time period. In January 2024, Avet announced a settlement with a separate putative class of Direct Purchaser Plaintiffs ("DPPs") in the Generic Pharmaceuticals Pricing Antitrust Litigation and Avet also announced a settlement with a separate putative class of End-Payer Plaintiffs ("EPPs") in June 2024. Under the terms of the settlement, the State AG Plaintiffs will receive $10 million with the funds to be held in escrow pending final Court approval of the settlement agreement. Once approved by the Court, all claims asserted by State AG Plaintiffs against the Company and Avet's former parent company, Emcure Pharmaceuticals Ltd., will be fully resolved and released. The settlement does not constitute an admission of liability by the Company. Announcement • Oct 31
Emcure Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024 Emcure Pharmaceuticals Limited announced that they will report Q2, 2025 results on Nov 07, 2024 Reported Earnings • Aug 15
First quarter 2025 earnings released: EPS: ₹7.95 (vs ₹7.93 in 1Q 2024) First quarter 2025 results: EPS: ₹7.95 (up from ₹7.93 in 1Q 2024). Revenue: ₹18.4b (up 14% from 1Q 2024). Net income: ₹1.44b (flat on 1Q 2024). Profit margin: 7.8% (down from 8.9% in 1Q 2024). The decrease in margin was driven by higher expenses. Announcement • Aug 07
Emcure Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 13, 2024 Emcure Pharmaceuticals Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Buy Or Sell Opportunity • Aug 06
Now 20% overvalued The stock has been flat over the last 90 days, currently trading at ₹1,300. The fair value is estimated to be ₹1,082, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has declined by 4.8%. Board Change • Jul 11
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. 5 independent directors (6 non-independent directors). Independent Director Shailesh Ayyangar was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 
